Integral Health Asset Management LLC lowered its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 25.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 300,000 shares of the biopharmaceutical company's stock after selling 100,000 shares during the period. Integral Health Asset Management LLC owned about 0.25% of Catalyst Pharmaceuticals worth $6,261,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also modified their holdings of CPRX. Castlekeep Investment Advisors LLC purchased a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter worth about $37,494,000. Bank of America Corp DE grew its stake in Catalyst Pharmaceuticals by 139.5% during the 4th quarter. Bank of America Corp DE now owns 1,568,791 shares of the biopharmaceutical company's stock valued at $32,741,000 after acquiring an additional 913,843 shares in the last quarter. abrdn plc purchased a new stake in Catalyst Pharmaceuticals during the 4th quarter valued at about $10,115,000. Arrowstreet Capital Limited Partnership grew its stake in Catalyst Pharmaceuticals by 131.4% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 698,152 shares of the biopharmaceutical company's stock valued at $14,570,000 after acquiring an additional 396,506 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in Catalyst Pharmaceuticals by 4.9% during the 4th quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company's stock valued at $175,957,000 after acquiring an additional 390,116 shares in the last quarter. Hedge funds and other institutional investors own 79.22% of the company's stock.
Catalyst Pharmaceuticals Price Performance
Shares of CPRX stock traded up $0.59 during mid-day trading on Friday, hitting $24.37. The stock had a trading volume of 988,043 shares, compared to its average volume of 1,107,865. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $14.75 and a fifty-two week high of $26.16. The firm has a market cap of $2.97 billion, a PE ratio of 20.65, a PEG ratio of 3.31 and a beta of 0.70. The company's 50-day simple moving average is $23.23 and its 200-day simple moving average is $22.47.
Insider Activity at Catalyst Pharmaceuticals
In related news, insider Brian Elsbernd sold 62,975 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the sale, the insider now owns 188,564 shares in the company, valued at $4,333,200.72. This trade represents a 25.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Gary Ingenito sold 44,000 shares of the firm's stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $23.63, for a total transaction of $1,039,720.00. Following the completion of the sale, the insider now owns 68,873 shares of the company's stock, valued at $1,627,468.99. This trade represents a 38.98% decrease in their position. The disclosure for this sale can be found here. Insiders sold 351,879 shares of company stock worth $8,214,815 over the last 90 days. Company insiders own 10.40% of the company's stock.
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on CPRX. Baird R W raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Monday, February 3rd. HC Wainwright restated a "buy" rating and issued a $35.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Stephens reaffirmed an "overweight" rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Finally, Robert W. Baird increased their target price on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research report on Monday, March 3rd. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $32.29.
Read Our Latest Stock Analysis on CPRX
About Catalyst Pharmaceuticals
(
Free Report)
Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
Recommended Stories
Before you consider Catalyst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Catalyst Pharmaceuticals wasn't on the list.
While Catalyst Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
